PSMA-PET/CT provided superior detection of prostate cancer lesions with better sensitivity than mpMRI. PSMA-PET/CT can be used to enhance locoregional mpMRI to provide improved detection and characterization of lesions.
INTRODUCTION AND OBJECTIVES: Current standard of care for prostate cancer detection is multiparametric MRI (mpMRI) and biopsy prior to active treatment. In recent years, prostate-specific membrane antigen (PSMA) ligands have been used in positron emission tomography (PET) to target prostate cancer cells for detection, however guidelines on its use are limited by its infancy. PSMA PET is a highly sensitive and specific scan that has been primarily used in detecting prostate cancer recurrence. PSMA PET may be combined with computed tomography (CT) or MRI, although few centres have access to PET/MRI machines. There is a growing role for PSMA PET/CT in primary staging. We aimed to examine how PSMA PET/CT could contribute to current standards of care by comparing mpMRI and PSMA PET/CT to prostatectomy histopathology.METHODS: We conducted a chart review from February 2015 to January 2017 of 50 male patients staged for prostate cancer using PSMA PET/CT and mpMRI who then underwent radical prostatectomy. Pre-operative PSMA PET/CT and mpMRI were paired with their corresponding histological tumor.RESULTS: A total of 50 male patients were included in this study, with a mean age of 64.9 years (AE 5.6), and PSA of 10.6 (AE 8.1). The median time between PSMA PET/CT and surgery was 5 weeks (range 0-21 weeks), and the median time between mpMRI and surgery was 18 weeks (IQR 13-25 weeks). The median time between mpMRI and PSMA PET/CT was 12 weeks (IQR 3-12.25 weeks). A total of 81 lesions were confirmed by histopathology. Fifty index lesions were confirmed by histopathology, all of which were detected by PSMA PET/ CT and 47 by mpMRI (100% vs. 94%). Thirty-one secondary lesions were confirmed by histopathology, 29 of which were detected by PSMA PET/CT and 16 by mpMRI (93.5% vs. 51.6%). PSMA had better sensitivity for index lesion localization than mpMRI (81.1% vs. 64.8%). Specificity was similar for PSMA PET/CT and mpMRI (84.6% vs. 82.7%). Forty-five patients (90%) were found to have multifocal disease on histopathology. PSMA predicted multifocal disease in 43 (86%) of patients (88.9% sensitivity, 40.0% specificity); mpMRI predicted multifocal disease poorly (10% sensitivity, 10% specificity).CONCLUSIONS: PSMA-PET/CT provided superior detection of prostate cancer lesions with better sensitivity than mpMRI. PSMA-PET/ CT can be used to enhance locoregional mpMRI to provide improved detection and characterization of lesions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.